Pathology Researcher obtains $200,000 to study the procoagulant cofactor, factor VIII 2011 June 27
YM Biosciences, a Mississauga based biotechnology company, has
partnered with the Queen's genomics facility through an agreement with
Harriet Feilotter to investigate a new small molecule drug against
myeloproliferative disease.
The drug, CYT387, targets JAK2, which is
often mutated in this disorder. Using patient samples taken at time
points following treatment, our lab is carrying out quantitative JAK2
mutation assays to help to determine whether or not the level of
mutated JAK2 in the blood of patients correlates with response to the
drug.
The study should be completed by 2012. We anticipate that
success with this study may pave the way for future interactions with
this Ontario-based company.
5/5
|